Legend Biotech Corp. ADR (LEGN): Price and Financial Metrics
GET POWR RATINGS... FREE!
LEGN Stock Price Chart Interactive Chart >
LEGN Price/Volume Stats
| Current price | $50.65 | 52-week high | $57.72 |
| Prev. close | $49.66 | 52-week low | $30.75 |
| Day low | $48.87 | Volume | 289,800 |
| Day high | $50.80 | Avg. volume | 746,404 |
| 50-day MA | $51.34 | Dividend yield | N/A |
| 200-day MA | $47.06 | Market Cap | 8.31B |
Legend Biotech Corp. ADR (LEGN) Company Bio
Legend Biotech Corp. is a holding company which engages in the discovery and development of novel cell therapies for oncology and other indications. It carries out its operations through the North America, and China geographical segments. The company was founded in May 2015 and is headquartered in Somerset, NJ.
Latest LEGN News From Around the Web
Below are the latest news stories about LEGEND BIOTECH CORP that investors may wish to consider to help them evaluate LEGN as an investment opportunity.
Genscript Bio Gets Booster From Subsidiary''s New Cancer DrugKey Takeaways: After years of losses, Legend Biotech’s new cancer drug Cavykti offers it a chance to finally start contributing revenue to its parent, Genscript Biotech Some analysts believe Genscript may have become profitable last year, but also worry over its mounting R&D and sales expenses By Emily Chan The good news is coming thick and fast these days for Genscript Biotech Corp. (1548.HK). In early January, it disclosed that China’s National Medical Products Administration (NMPA) accepted its new drug application (NDA) for Cilta-cel , a chimeric antigen receptor T-cell (CAR-T) therapy being developed by its Legend Biotech (NASDAQ: LEGN ) subsidiary. Last Wednesday, it announced that sales of the new drug, marketed in the U.S. under the Carvykti name for treatment of multiple myelom... |
Genscript Biotech (GNNSF) Gets Booster From Subsidiary’s New Cancer DrugAfter years of losses, Legend Biotech’s new cancer drug Cavykti offers it a chance to finally start contributing revenue to its parent, Genscript Biotech. |
Investing in Legend Biotech Corporation (LEGN) might be an excellent idea, but the stock is currently overvalued/undervaluedThe share price of Legend Biotech Corporation (NASDAQ:LEGN) rose to $50.50 per share on Tuesday from $50.13. While Legend Biotech Corporation has overperformed by 0.74%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, LEGN rose by 34.81%, with highs and lows ranging from $57.72 to $30.75, […] |
Legend Biotech: CARTITUDE-4 Study A Success (NASDAQ:LEGN)Legend Biotech and partner JNJ announced positive topline results from the CARTITUDE-4 trial of Carvykti last week. See why LEGN stock is a Buy. |
Legend Biotech Announces Phase 3 CARTITUDE-4 Study of CARVYKTI® (ciltacabtagene autoleucel) Has Met Its Primary Endpoint in the Treatment of Patients with Relapsed and Refractory Multiple MyelomaLegend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global biotechnology company developing, manufacturing and commercializing novel therapi |
LEGN Price Returns
| 1-mo | 2.14% |
| 3-mo | -1.65% |
| 6-mo | 9.89% |
| 1-year | 19.09% |
| 3-year | N/A |
| 5-year | N/A |
| YTD | 1.46% |
| 2022 | 7.10% |
| 2021 | 65.52% |
| 2020 | N/A |
| 2019 | N/A |
| 2018 | N/A |
Loading social stream, please wait...